Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 August 2008Website:
http://www.ibioinc.comNext earnings report:
15 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:59:38 GMTDividend
Analysts recommendations
Institutional Ownership
IBIO Latest News
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.
iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.
Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.
Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).
What type of business is iBio?
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
What sector is iBio in?
iBio is in the Healthcare sector
What industry is iBio in?
iBio is in the Biotechnology industry
What country is iBio from?
iBio is headquartered in United States
When did iBio go public?
iBio initial public offering (IPO) was on 19 August 2008
What is iBio website?
https://www.ibioinc.com
Is iBio in the S&P 500?
No, iBio is not included in the S&P 500 index
Is iBio in the NASDAQ 100?
No, iBio is not included in the NASDAQ 100 index
Is iBio in the Dow Jones?
No, iBio is not included in the Dow Jones index
When does iBio report earnings?
The next expected earnings date for iBio is 15 August 2024